Dynamic contrast-enhanced MRI of benign prostatic hyperplasia and prostatic carcinoma: correlation with angiogenesis

Clinical Radiology

Volumn 63, Issue 2, 2008, Pages 153-159

  Ren, J ^a   Huan, Y ^a   Wang, H ^a   Chang, Y J ^a   Zhao, H T ^a   Ge, Y L ^a   Liu, Y ^a   Yang, Y ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HISTOLOGY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTEIN EXPRESSION;

AGED; AGED, 80 AND OVER; CARCINOMA; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 37849023989     PISSN: 00099260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crad.2007.07.023     Document Type: Article

References (29)

1. Greenlee R.T., Murray T., Bolden S., et al. Cancer statistics. CA Cancer J Clin 50 (2000) 7-33
2. Robert A., Andrew C., Richard W., et al. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. CA Cancer J Clin 51 (2001) 38-75
3. Perrotti M., Han K.R., Epstein R.E., et al. Prospective evaluation of endorectal magnetic resonance imaging to detect tumor foci in men with prior negative prostastic biopsy: a pilot study. J Urol 162 (1999) 1314-1317
4. Bigler S.A., Deering R.E., and Brawer M.K. Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol 24 (1993) 220-226
5. Hawighorst H., Knapstein P.G., Knopp M.V., et al. Cervical carcinoma: standard and pharmacokinetic analysis of time-intensity curve for assessment of tumours angiogenesis and patient survival. MAGMA 8 (1999) 55-62
6. Checkley D., Tessier J.J., Kendrew J., et al. Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours. Br J Cancer 89 (2003) 1889-1895
7. Preziosi P., Orlacchio A., Giambattista G.D., et al. Enhancement patterns of prostate cancer in dynamic MRI. Eur Radiol 13 (2003) 925-930
8. Rouviere O., Raudrant A., Ecochard R., et al. Characterization of time-enhancement curives of benign and malignant prostate tissue at dynamic MR imaging. Eur Radiol 13 (2003) 931-942
9. Kiessling F., Lichy M., Grobholz R., et al. Simple models improve the discrimination of prostate cancers from the peripheral gland by T1-weighted dynamic MRI. Eur Radiol 14 (2004) 1793-1801
10. Weidner N., Semple J.P., Welch W.R., et al. Tumour angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324 (1991) 1-8
11. Hara N., Okuizumi M., Koike H., et al. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer. Prostate 62 (2005) 140-147
12. Heverhagen J.T., von H., Baudendistel K.T., et al. Benign prostate hyperplasia: evaluation of treatment response with DCE MRI. MAGMA 17 (2004) 5-11
13. Bammer R. Basic principles of diffusion-weighted imaging. Eur J Radiol 45 (2003) 169-184
14. Gibbs P., Tozer D.J., Liney G.P., et al. Comparison of quantitative T2 mapping and diffusion-weighted imaging in the normal and pathologic prostate. Magn Reson Med 46 (2001) 1054-1058
15. Folkman J., Watson K., Ingber D., et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339 (1989) 58-61
16. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 333 (1995) 1757-1763
17. Fox S.B. Tumour angiogenesis and prognosis. Histopathology 30 (1997) 294-301
18. Angeletti C.A., Lucchi M., Fontanini G., et al. Prognostic significance of tumoural angiogenesis in completely resected late stage lung carcinoma (stage IIIA-N2). Cancer 78 (1996) 409-415
19. Tuncbilek N., Karakas H.M., and Okten O.O. Dynamic magnetic resonance imaging in determining histopathological prognostic factors of invasive breast cancers. Eur J Radiol 53 (2005) 199-205
20. Egmont-Petersen M., Hogendoorn P.C., Geest R.J., et al. Detection of areas with viable remnant tumour in postchemotherapy patients with Ewing's sarcoma by dynamic contrast-enhanced MRI using pharmacokinetic modeling. Magn Reson Imaging 18 (2000) 525-535
21. Padhani A.R., Gapinski C.J., Macvicar D.A., et al. Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol 55 (2000) 99-109
22. Hawighorst H., Knapstein P.G., Knopp M.V., et al. Uterine cervical carcinoma: comparison of standard and pharmacokinetic analysis of time-intensity curves for assessment of tumour angiogenesis and patient survival. Cancer Res 58 (1998) 3598-3602
23. Juergen F.S., Joachim V., Fritz S., et al. Solitary pulmonary nodules: dynamic contrast-enhanced MR imaging-perfusion differences in malignant and benign lesions. Radiology 232 (2004) 544-553
24. Deering R.E., Bigler S.A., Brawer M.K., et al. Microvascularity in benign prostatic hyperplasia. Prostate 26 (1995) 111-115
25. Krupski T., Harding M.A., Herce M.E., et al. The role of vascular endothelial growth factor in the tissue specific in vivo growth of prostate cancer cells. Growth Factors 18 (2001) 287-302
26. Cetinkaya M., Gunce S., Ulusoy E., et al. Relationship between prostate specific antigen density, microvessel density and prostatic volume in benign prostatic hyperpiasia and advanced prostatic carcinoma. Int Urol Nephrol 30 (1998) 581-585
27. Rehman S., and Jayson G.C. Molecular imaging of antiangiogenic agents. Oncologist 10 (2005) 92-103
28. Karam J.A., Mason R.P., Koeneman K.S., et al. Molecular imaging in prostate cancer. J Cell Biochem 90 (2003) 473-483
29. Bagnall S., and Klotz L. Conservative versus radical therapy of prostate cancer: how have recent advances in molecular markers and imaging enhanced our ability to prognosticate risk?. Oncol 30 (2003) 587-595